PAOG 300% ROI Potential w/Bullish $0.015 Analyst Outlook and Updated Financials
September 09 2020 - 9:40AM
InvestorsHub NewsWire
September 9,
2020 -- InvestorsHub NewsWire -- via NextBigTicker -- Goldman Small
Cap Research updated research on PAO Group, Inc. (USOTC:
PAOG) yesterday following PAOG reinstating its “Current
Information” status with OTC Markets. Goldman’s review
included a bullish rating and $0.015 PPS 12-month
target. At $0.004, PAOG has a 300% ROI
potential.
AmericanBULLS is
also rates PAOG as bullish (americanbulls.com/PAOG).
“The last pattern
detected was bullish with positive
implications.”
The PAOG PPS
remains well above its 50 day and 200 day moving averages which are
both climbing as the PPS bases between $0.003 and $0.004 preparing
for its next climb.
PAOG recently
entered the biotech sector with a proprietary treatment for
respiratory disorders derived from a patented cannabis extract.
The treatment is called RespRx. The company reports
having run a trial of its proprietary treatment on COVID-19
patients that has compelled the company to apply for the
Coronavirus Treatment Acceleration Program
(CTAP).
Disclaimer:
NextBigTicker.com (NBT)is a third party publisher
and news dissemination service provider. NBT is NOT affiliated
in any manner with any company mentioned herein. NBT is news
dissemination solutions provider and are NOT a registered
broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. NBT's
market updates, news alerts and corporate profiles are NOT a
solicitation or recommendation to buy, sell or hold securities. The
material in this release is intended to be strictly informational
and is NEVER to be construed or interpreted as research material.
All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial
professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS
RELEASE.
Disclaimer/Safe
Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur.
Source: www.nextbigticker.com
Other movers to watch are
GAXY,
VRUS, and
BBRW.
SOURCE: NextBigTicker
Verus (CE) (USOTC:VRUS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Verus (CE) (USOTC:VRUS)
Historical Stock Chart
From Dec 2023 to Dec 2024